- Home
- PRQR vs IPSC Comparison
PRQR vs IPSC Comparison
Compare PRQR & IPSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PRQR | IPSC |
|---|---|---|
| Founded | 2012 | 2019 |
| Country | Netherlands | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 262.5M | 248.1M |
| IPO Year | 2014 | 2021 |
Fundamental Metrics
Financial Performance| Metric | PRQR | IPSC |
|---|---|---|
| Price | $1.29 | $1.48 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 5 |
| Target Price | ★ $7.78 | $4.75 |
| AVG Volume (30 Days) | 791.5K | ★ 883.4K |
| Earning Date | 11-05-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 91.30 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $109,164,000.00 |
| Revenue This Year | $8.25 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 1556.76 |
| 52 Week Low | $1.30 | $0.44 |
| 52 Week High | $3.00 | $2.97 |
Technical Indicators
Market Signals| Indicator | PRQR | IPSC |
|---|---|---|
| Relative Strength Index (RSI) | 25.22 | 43.63 |
| Support Level | N/A | $1.22 |
| Resistance Level | $1.99 | $2.45 |
| Average True Range (ATR) | 0.09 | 0.16 |
| MACD | -0.01 | 0.03 |
| Stochastic Oscillator | 10.87 | 49.15 |
Price Performance
Historical ComparisonAbout PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics. Geographically, the company operates in United States.
About IPSC Century Therapeutics Inc.
Century Therapeutics Inc is a biotechnology company harnessing the power of allogeneic pluripotent stem cell therapies to develop potentially curative cell therapy products for autoimmune diseases, including type 1 diabetes, or T1D, and cancer. Its beta islet, T cell and NK cell programs are allogeneic, meaning it is derived from healthy donors for use in any patient, rather than being sourced from an individual for their own specific use, as is the case with autologous T cells. The cell types it can generate from iPSCs, including iPSC-derived beta islet cells, iPSC-derived CD4+ and CD8+ alphabeta T cells, or alphabeta iT cells, and iPSC- natural killer cells, or iNK cells.